Jan 15, 2021
Isofol to present gene expression results from the completed Phase I/IIa ISO-CC-005 study today at ASCO-GI 2021 and updates of the timing of the interim analysis in the AGENT study
Mar 30, 2020
Gene Expression Data From New Analysis Method Supports That a Larger Proportion of Patients will Benefit From Arfolitixorin
Feb 18, 2020
The First Patient Included in Japan in Isofol's Phase 3 AGENT Study
Jan 30, 2020
Isofol Medical: The Phase 1/2a Study ISO-CC-005 is Completed
Jan 30, 2020
Isofol Medical: Over 200 Patients Now Randomized in the Global Phase 3 AGENT Study
Jan 24, 2020
The First Patient Included in Australia in Isofol's Phase 3 AGENT Study
Dec 20, 2019
Patent Approved in Japan for Isofol's Drug Candidate Arfolitixorin
Oct 18, 2019
Isofol Receives Positive Feedback From PMDA in Japan, Expanding Ongoing Global Pivotal Phase 3 AGENT Trial in First Line Metastatic Colorectal Cancer
Sep 12, 2019
Isofol Announces that an Abstract has been Accepted for Presentation at the 2019 ESMO Congress
Aug 15, 2019
Isofol Announces Management Team Evolution With Appointment of Dr. Roger Tell as Chief Medical Officer
Jul 15, 2019
Isofol Announces Recent Advisory Board Meeting Covering Development Plan for Arfolitixorin
Jun 25, 2019
Isofol Receives Clinical Use Patent Approval in the United States for Drug Candidate arfolitixorin
Jun 10, 2019
Isofol Announces Election of Three New Board Members
May 08, 2019
Isofol Reports 58 % Overall Response Rate in Patients with Metastatic Colorectal Cancer in Phase 1/2a Open Label Extension Study with Arfolitixorin
Feb 01, 2019
Isofol Reports All Employees Participate in Newly Created Share Warrant Program
Jan 17, 2019
Isofol Reports Early Tumor Shrinkage in Patients With Colorectal Cancer in Phase 1/2a Open Label Extension Study with Arfolitixorin
Dec 18, 2018
First Patient Enrolled in Isofol's Pivotal Phase 3 AGENT Study in 1st Line Metastatic Colorectal Cancer